Sara Akhavanfard

6.6k total citations · 1 hit paper
15 papers, 1.4k citations indexed

About

Sara Akhavanfard is a scholar working on Molecular Biology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Sara Akhavanfard has authored 15 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Molecular Biology, 6 papers in Oncology and 4 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Sara Akhavanfard's work include Renal and related cancers (4 papers), Cancer Genomics and Diagnostics (3 papers) and Lung Cancer Treatments and Mutations (3 papers). Sara Akhavanfard is often cited by papers focused on Renal and related cancers (4 papers), Cancer Genomics and Diagnostics (3 papers) and Lung Cancer Treatments and Mutations (3 papers). Sara Akhavanfard collaborates with scholars based in United States, Canada and Iran. Sara Akhavanfard's co-authors include A. John Iafrate, David N. Louis, Daniel A. Haber, Kenneth Aldape, Long P. Le, Mai Nitta, Boryana Zhelyazkova, Daniel P. Cahill, Ladan Fazlollahi and Matija Snuderl and has published in prestigious journals such as Science, Nature Communications and Journal of Clinical Oncology.

In The Last Decade

Sara Akhavanfard

15 papers receiving 1.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Mosaic Amplification of Multiple Receptor Tyrosine Kinase Genes in Glioblastoma

2011 498 citations Matija Snuderl, Ladan Fazlollahi et al. Cancer Cell profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Sara Akhavanfard United States	8	801	504	356	340	248	15	1.4k
Joshua M. Francis United States	16	1.5k 1.9×	540 1.1×	454 1.3×	156 0.5×	221 0.9×	26	2.1k
Ajay Pandita Canada	19	1.1k 1.4×	603 1.2×	766 2.2×	344 1.0×	609 2.5×	26	2.1k
Gunnar Wrobel Germany	19	758 0.9×	287 0.6×	275 0.8×	366 1.1×	131 0.5×	21	1.5k
Julie Koeman United States	20	923 1.2×	462 0.9×	365 1.0×	128 0.4×	286 1.2×	26	1.5k
Abdullah Mahmood Ali United States	20	1.5k 1.8×	309 0.6×	244 0.7×	147 0.4×	90 0.4×	60	2.0k
Zachary A. Kohutek United States	11	433 0.5×	358 0.7×	494 1.4×	175 0.5×	386 1.6×	24	1.1k
María D. Odero Spain	32	1.8k 2.3×	482 1.0×	476 1.3×	603 1.8×	138 0.6×	88	2.9k
Markus Heidenblad Sweden	14	1.1k 1.3×	655 1.3×	332 0.9×	60 0.2×	261 1.1×	19	1.7k
Sana Yokoi Japan	21	870 1.1×	297 0.6×	498 1.4×	143 0.4×	378 1.5×	43	1.4k
Adina Figl Germany	7	909 1.1×	285 0.6×	535 1.5×	141 0.4×	185 0.7×	8	1.6k

Countries citing papers authored by Sara Akhavanfard

Since Specialization

Citations

This map shows the geographic impact of Sara Akhavanfard's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sara Akhavanfard with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sara Akhavanfard more than expected).

Fields of papers citing papers by Sara Akhavanfard

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sara Akhavanfard. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sara Akhavanfard. The network helps show where Sara Akhavanfard may publish in the future.

Co-authorship network of co-authors of Sara Akhavanfard

This figure shows the co-authorship network connecting the top 25 collaborators of Sara Akhavanfard. A scholar is included among the top collaborators of Sara Akhavanfard based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sara Akhavanfard. Sara Akhavanfard is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

15 of 15 papers shown

Akhavanfard, Sara, et al.. (2021). 5′ <b><i>ALK</i></b> Amplification in Neuroblastoma: A Case Report. Case Reports in Oncology. 14(1). 585–591. 2 indexed citations

Akhavanfard, Sara, Roshan Padmanabhan, Lamis Yehia, Feixiong Cheng, & Charis Eng. (2020). Comprehensive germline genomic profiles of children, adolescents and young adults with solid tumors. Nature Communications. 11(1). 2206–2206. 39 indexed citations

Akhavanfard, Sara, Lamis Yehia, Roshan Padmanabhan, et al.. (2020). Germline EGFR variants are over-represented in adolescents and young adults (AYA) with adrenocortical carcinoma. Human Molecular Genetics. 29(22). 3679–3690. 6 indexed citations

Bosworth, Colleen M., et al.. (2017). Heteroplasmic shifts in tumor mitochondrial genomes reveal tissue-specific signals of relaxed and positive selection. Human Molecular Genetics. 26(15). 2912–2922. 48 indexed citations

Alexandrescu, Sanda, Sara Akhavanfard, Marian H. Harris, & Sara O. Vargas. (2017). Clinical, Pathologic, and Genetic Features of Wilms Tumors With WTX Gene Mutation. Pediatric and Developmental Pathology. 20(2). 105–111. 4 indexed citations

Alexandrescu, Sanda, Sara Akhavanfard, Marian H. Harris, & Sara O. Vargas. (2016). Clinical, pathologic, and genetic features of Wilms tumors with WTX gene mutation. Pediatric and Developmental Pathology. 3 indexed citations

Akhavanfard, Sara, Sara O. Vargas, Moonjoo Han, et al.. (2013). Inactivation of the tumor suppressor WTX in a subset of pediatric tumors. Genes Chromosomes and Cancer. 53(1). 67–77. 5 indexed citations

Moisan, Annie, Miguel N. Rivera, Sutada Lotinun, et al.. (2012). The WTX Tumor Suppressor Regulates Mesenchymal Progenitor Cell Fate Specification. Developmental Cell. 22(5). 1109–1117. 1 indexed citations

Moisan, Annie, Miguel N. Rivera, Sutada Lotinun, et al.. (2011). The WTX Tumor Suppressor Regulates Mesenchymal Progenitor Cell Fate Specification. Developmental Cell. 20(5). 583–596. 34 indexed citations

10.

Xiao, Hong, Hiroshi Yamaguchi, Dora Dias‐Santagata, et al.. (2011). Molecular characteristics and biological behaviours of the oncocytic and pancreatobiliary subtypes of intraductal papillary mucinous neoplasms. The Journal of Pathology. 224(4). 508–516. 48 indexed citations

11.

Snuderl, Matija, Ladan Fazlollahi, Long P. Le, et al.. (2011). Mosaic Amplification of Multiple Receptor Tyrosine Kinase Genes in Glioblastoma. Cancer Cell. 20(6). 810–817. 498 indexed citations breakdown →

12.

Ting, David T., Doron Lipson, Suchismita Paul, et al.. (2011). Aberrant Overexpression of Satellite Repeats in Pancreatic and Other Epithelial Cancers. Science. 331(6017). 593–596. 393 indexed citations

13.

Dias‐Santagata, Dora, Sara Akhavanfard, Georgiana Kuhlmann, et al.. (2010). Rapid targeted mutational analysis of human tumours: a clinical platform to guide personalized cancer medicine. EMBO Molecular Medicine. 2(5). 146–158. 282 indexed citations

14.

Growdon, Whitfield B., Sara Akhavanfard, Esther Oliva, et al.. (2008). Decreased survival in EGFR gene amplified vulvar carcinoma. Gynecologic Oncology. 111(2). 289–297. 46 indexed citations

15.

Entezari, Vahid, et al.. (2005). Docetaxel, cisplatin, 5-flourouracil x 3 days (DCF3) compared to docetaxel, cisplatin, 5-flourouracil x 5 days (DCF5) chemotherapy for patients with metastatic or locally advanced, unresectable gastric carcinoma (MGC). Journal of Clinical Oncology. 23(16_suppl). 4258–4258. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact